Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896834526> ?p ?o ?g. }
- W2896834526 endingPage "894" @default.
- W2896834526 startingPage "885" @default.
- W2896834526 abstract "BackgroundThe antibiotic minocycline has neuroprotective and anti-inflammatory properties that could prevent or reverse progressive neuropathic changes implicated in recent-onset schizophrenia. In the BeneMin study, we aimed to replicate the benefit of minocycline on negative symptoms reported in previous pilot studies, and to understand the mechanisms involved.MethodsIn this randomised, double-blind, placebo-controlled trial, we recruited people with a schizophrenia-spectrum disorder that had begun within the past 5 years with continuing positive symptoms from 12 National Health Service (NHS) trusts. Participants were randomly assigned according to an automated permuted blocks algorithm, stratified by pharmacy, to receive minocycline (200 mg per day for 2 weeks, then 300 mg per day for the remainder of the 12-month study period) or matching placebo, which were added to their continuing treatment. The primary clinical outcome was the negative symptom subscale score of the Positive and Negative Syndrome Scales (PANSS) across follow-ups at months 2, 6, 9, and 12. The primary biomarker outcomes were medial prefrontal grey-matter volume, dorsolateral prefrontal cortex activation during a working memory task, and plasma concentration of interleukin 6. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN49141214, and the EU Clinical Trials register (EudraCT) number is 2010-022463-35I.FindingsBetween April 16, 2013, and April 30, 2015, we recruited 207 people and randomly assigned them to receive minocycline (n=104) or placebo (n=103). Compared with placebo, the addition of minocycline had no effect on ratings of negative symptoms (treatment effect difference −0·19, 95% CI −1·23 to 0·85; p=0·73). The primary biomarker outcomes did not change over time and were not affected by minocycline. The groups did not differ in the rate of serious adverse events (n=11 in placebo group and n=18 in the minocycline group), which were mostly due to admissions for worsening psychiatric state (n=10 in the placebo group and n=15 in the minocycline group). The most common adverse events were gastrointestinal (n=12 in the placebo group, n=19 in the minocycline group), psychiatric (n=16 in placebo group, n=8 in minocycline group), nervous system (n=8 in the placebo group, n=12 in the minocycline group), and dermatological (n=10 in the placebo group, n=8 in the minocycline group).InterpretationMinocycline does not benefit negative or other symptoms of schizophrenia over and above adherence to routine clinical care in first-episode psychosis. There was no evidence of a persistent progressive neuropathic or inflammatory process underpinning negative symptoms. Further trials of minocycline in early psychosis are not warranted until there is clear evidence of an inflammatory process, such as microgliosis, against which minocycline has known efficacy.FundingNational Institute for Health Research Efficacy and Mechanism Evaluation (EME) programme, an MRC and NIHR partnership. The antibiotic minocycline has neuroprotective and anti-inflammatory properties that could prevent or reverse progressive neuropathic changes implicated in recent-onset schizophrenia. In the BeneMin study, we aimed to replicate the benefit of minocycline on negative symptoms reported in previous pilot studies, and to understand the mechanisms involved. In this randomised, double-blind, placebo-controlled trial, we recruited people with a schizophrenia-spectrum disorder that had begun within the past 5 years with continuing positive symptoms from 12 National Health Service (NHS) trusts. Participants were randomly assigned according to an automated permuted blocks algorithm, stratified by pharmacy, to receive minocycline (200 mg per day for 2 weeks, then 300 mg per day for the remainder of the 12-month study period) or matching placebo, which were added to their continuing treatment. The primary clinical outcome was the negative symptom subscale score of the Positive and Negative Syndrome Scales (PANSS) across follow-ups at months 2, 6, 9, and 12. The primary biomarker outcomes were medial prefrontal grey-matter volume, dorsolateral prefrontal cortex activation during a working memory task, and plasma concentration of interleukin 6. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN49141214, and the EU Clinical Trials register (EudraCT) number is 2010-022463-35I. Between April 16, 2013, and April 30, 2015, we recruited 207 people and randomly assigned them to receive minocycline (n=104) or placebo (n=103). Compared with placebo, the addition of minocycline had no effect on ratings of negative symptoms (treatment effect difference −0·19, 95% CI −1·23 to 0·85; p=0·73). The primary biomarker outcomes did not change over time and were not affected by minocycline. The groups did not differ in the rate of serious adverse events (n=11 in placebo group and n=18 in the minocycline group), which were mostly due to admissions for worsening psychiatric state (n=10 in the placebo group and n=15 in the minocycline group). The most common adverse events were gastrointestinal (n=12 in the placebo group, n=19 in the minocycline group), psychiatric (n=16 in placebo group, n=8 in minocycline group), nervous system (n=8 in the placebo group, n=12 in the minocycline group), and dermatological (n=10 in the placebo group, n=8 in the minocycline group). Minocycline does not benefit negative or other symptoms of schizophrenia over and above adherence to routine clinical care in first-episode psychosis. There was no evidence of a persistent progressive neuropathic or inflammatory process underpinning negative symptoms. Further trials of minocycline in early psychosis are not warranted until there is clear evidence of an inflammatory process, such as microgliosis, against which minocycline has known efficacy." @default.
- W2896834526 created "2018-10-26" @default.
- W2896834526 creator A5002936880 @default.
- W2896834526 creator A5009512673 @default.
- W2896834526 creator A5014286457 @default.
- W2896834526 creator A5017525685 @default.
- W2896834526 creator A5019095577 @default.
- W2896834526 creator A5019391929 @default.
- W2896834526 creator A5025660060 @default.
- W2896834526 creator A5027372267 @default.
- W2896834526 creator A5029756580 @default.
- W2896834526 creator A5035759912 @default.
- W2896834526 creator A5040985764 @default.
- W2896834526 creator A5045174960 @default.
- W2896834526 creator A5047579218 @default.
- W2896834526 creator A5052278006 @default.
- W2896834526 creator A5054333266 @default.
- W2896834526 creator A5055886512 @default.
- W2896834526 creator A5075289365 @default.
- W2896834526 creator A5077349618 @default.
- W2896834526 creator A5080581341 @default.
- W2896834526 creator A5080723337 @default.
- W2896834526 creator A5084599446 @default.
- W2896834526 creator A5085756728 @default.
- W2896834526 creator A5087009968 @default.
- W2896834526 date "2018-11-01" @default.
- W2896834526 modified "2023-10-16" @default.
- W2896834526 title "The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial" @default.
- W2896834526 cites W1966396713 @default.
- W2896834526 cites W1969833165 @default.
- W2896834526 cites W1978238793 @default.
- W2896834526 cites W1982852824 @default.
- W2896834526 cites W1989502746 @default.
- W2896834526 cites W1991964306 @default.
- W2896834526 cites W1992857340 @default.
- W2896834526 cites W2006455719 @default.
- W2896834526 cites W2009801894 @default.
- W2896834526 cites W2018922612 @default.
- W2896834526 cites W2022433310 @default.
- W2896834526 cites W2026508141 @default.
- W2896834526 cites W2030067400 @default.
- W2896834526 cites W2044756089 @default.
- W2896834526 cites W2058046532 @default.
- W2896834526 cites W2061187735 @default.
- W2896834526 cites W2061560549 @default.
- W2896834526 cites W2066738717 @default.
- W2896834526 cites W2080248624 @default.
- W2896834526 cites W2084588595 @default.
- W2896834526 cites W2089868642 @default.
- W2896834526 cites W2127679160 @default.
- W2896834526 cites W2136686417 @default.
- W2896834526 cites W2144536780 @default.
- W2896834526 cites W2145240519 @default.
- W2896834526 cites W2156340235 @default.
- W2896834526 cites W2415959686 @default.
- W2896834526 cites W2557675632 @default.
- W2896834526 cites W2587232605 @default.
- W2896834526 cites W2619378610 @default.
- W2896834526 cites W2743887053 @default.
- W2896834526 cites W2753594835 @default.
- W2896834526 cites W2787897432 @default.
- W2896834526 cites W2801812045 @default.
- W2896834526 cites W2896834526 @default.
- W2896834526 cites W2952123642 @default.
- W2896834526 cites W79347247 @default.
- W2896834526 doi "https://doi.org/10.1016/s2215-0366(18)30345-6" @default.
- W2896834526 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6206257" @default.
- W2896834526 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30322824" @default.
- W2896834526 hasPublicationYear "2018" @default.
- W2896834526 type Work @default.
- W2896834526 sameAs 2896834526 @default.
- W2896834526 citedByCount "116" @default.
- W2896834526 countsByYear W28968345262018 @default.
- W2896834526 countsByYear W28968345262019 @default.
- W2896834526 countsByYear W28968345262020 @default.
- W2896834526 countsByYear W28968345262021 @default.
- W2896834526 countsByYear W28968345262022 @default.
- W2896834526 countsByYear W28968345262023 @default.
- W2896834526 crossrefType "journal-article" @default.
- W2896834526 hasAuthorship W2896834526A5002936880 @default.
- W2896834526 hasAuthorship W2896834526A5009512673 @default.
- W2896834526 hasAuthorship W2896834526A5014286457 @default.
- W2896834526 hasAuthorship W2896834526A5017525685 @default.
- W2896834526 hasAuthorship W2896834526A5019095577 @default.
- W2896834526 hasAuthorship W2896834526A5019391929 @default.
- W2896834526 hasAuthorship W2896834526A5025660060 @default.
- W2896834526 hasAuthorship W2896834526A5027372267 @default.
- W2896834526 hasAuthorship W2896834526A5029756580 @default.
- W2896834526 hasAuthorship W2896834526A5035759912 @default.
- W2896834526 hasAuthorship W2896834526A5040985764 @default.
- W2896834526 hasAuthorship W2896834526A5045174960 @default.
- W2896834526 hasAuthorship W2896834526A5047579218 @default.
- W2896834526 hasAuthorship W2896834526A5052278006 @default.
- W2896834526 hasAuthorship W2896834526A5054333266 @default.
- W2896834526 hasAuthorship W2896834526A5055886512 @default.
- W2896834526 hasAuthorship W2896834526A5075289365 @default.
- W2896834526 hasAuthorship W2896834526A5077349618 @default.
- W2896834526 hasAuthorship W2896834526A5080581341 @default.